Index 189 Inflammatory bowel disease, 114, 119 Insufficient sleep syndrome, 103 Interferon therapy, 120 International Classification of Sleep Disorders (ICSD), 4, 5, 10, 67, 70, 81, 89, 99, 141 L Laceration, 118 Lamotrigine, 43, 72, 117, 121 Laryngospasm, 112 Levodopa, 117, 183 Limit-setting sleep disorder, 55, 84, 103 Lorazepam, 130, 131, 132, 138, 179 L-tryptophan, 174 M Mania, 58, 137 Melatonin, 47, 58, 59, 61, 62, 86, 175, 176, 177 Menopause, 40, 42, 72, 119, 174, 183 Menses, 119 Metabolic rate, 26, 28, 29, 30, 31, 34, 69, 91 Methylxanthines, 112, 150 Milk allergy, 114, 119 Milk-protein intolerance, 55 Monoamine oxidase inhibitors (MAOIs), 130, 135 Mood, 6, 24, 28, 29, 30, 34, 35, 40, 43, 61, 70, 72, 73, 127, 129, 132 Morphine, 113 Multiple sclerosis, 120 Multiple Sleep Latency Test (MSLT), 24, 26, 28, 29, 30, 31, 32, 34, 43, 48, 68, 89, 91, 95, 144, 146, 147 Muscular dystrophy, 117, 120 Musculoskeletal, 119 Myelopathy, 117, 120 Myocardial infarction, 113, 119 Myopathy, 120 N Narcolepsy, 42, 43, 99, 101, 142, 143, 144, 145, 146, 147, 150 Neck, 118 Nefazodone, 91, 130 Neuropathy, 117, 120 Nicotine, 100, 128, 138, 163 Nightmares, 117, 128, 134, 136, 137, 142, 144, 148 Nocturnal eating or drinking syndrome, 103 Nortriptyline, 112, 130 NREM sleep, 8, 115, 158, 159, 181 O Obstructive sleep apnea, 25, 42, 70, 95, 99, 101, 111, 141, 142, 143, 144, 146, 147, 148, 149, 150 Opiates, 86, 128, 150, 183 Orthopnea, 113, 118 Over-the-counter (OTC) sleep aids, 17, 74, 102, 138, 175 Oxazepam, 74, 138, 139, 177 Oxcarbazepine, 121 P Pain, 4, 8, 11, 39, 42, 68, 72, 85, 110, 112, 114, 119, 173, 183 Panic disorder, 16, 134, 135, 164, 165 Parkinson’s disease, 72, 117, 119 Paroxetine, 91, 113, 130, 133, 135 Peptic ulcer disease (PUD), 114, 119 Pergolide, 117, 183 Periodic limb movement disorder (PLMD), 25, 41, 42, 95, 101, 115, 116, 117, 141, 142, 144, 145, 146, 147, 148, 150, 178, 183 Pharmacotherapy, 58, 105, 116 Pharynx, 118, 143 Phenelzine, 130 Phenytoin, 121 Phototherapy, 47, 58, 59, 61, 113, 165 Polysomnogram (PSG), 47, 48, 67, 69, 70, 73, 82, 83, 85, 89, 90, 91, 92, 95, 104, 109, 111, 114, 115, 133, 138, 146, 147, 148 Posttraumatic stress disorder, 57, 136 Prader-Willi syndrome, 61 Pramipexole, 144, 150, 183 Pregnancy, 41, 70, 116, 119, 174 Premenstrual dysphoric disorder, 128 Prostate, 15, 114, 119
190 Index Proton pump inhibitors, 114 Psychophysiologic hyperarousal, 24, 28, 30, 35, 82, 100, 155, 156 Psychophysiological insomnia, 5, 6, 25, 26, 27, 29, 30, 31, 32, 35, 40, 43, 67, 68, 69, 70, 71, 72, 73, 81, 84, 90, 91, 95, 96, 99, 101, 104, 173, 177 R Radiculopathy, 117, 120 Rebound, 31, 74, 130, 139, 168, 178, 180, 181, 182, 183 Relaxation therapy, 35, 74, 105, 117, 150, 160, 165 REM sleep, 8, 27, 83, 116, 117, 121, 127, 130, 132, 134, 135, 136, 137, 138, 139, 144, 145, 147 Renal disease, 115, 119 Respiratory disturbance index (RDI), 42, 143, 148 Restless legs syndrome (RLS), 41, 42, 47, 101,103, 141, 142, 143, 144, 145, 147, 148, 149, 150, 174, 178, 180, 183 Rett syndrome, 61, 62 Reverse first night effect, 83, 85 Rheumatoid disorders, 115, 119 Rhinitis, 112, 118, 175 Ropinerole, 150, 183 S Sanfilippo syndrome, 61 Schizophrenia, 15, 136, 137, 176 Seasonal affective disorder, 128, 137 Sedative hypnotics, 11, 16, 17, 43, 48, 72, 73, 74, 85, 86, 92, 95, 103, 112, 113, 114, 115, 149, 150, 167, 168, 175 Seizures, 120 121, 128, 139, 147 Separation anxiety disorder, 128 Serotonin reuptake inhibitors (SSRI), 43, 72, 113, 114, 130, 133, 135, 136, 174 Sertraline, 130, 133, 135 Shift work, 25, 42, 70, 100, 182 Sinusitis, 112 Sleep efficiency, 6, 25, 29, 34, 61, 77, 83, 86, 91, 128, 132, 133, 134, 137, 176, 177, 178, 181 Sleep hygiene, 34, 40, 41, 47, 48, 67, 70, 71, 73, 74, 85, 86, 92, 99, 100, 101, 102, 104, 105, 131, 143, 148, 150, 160, 162, 163, 174 Sleep latency, 5, 6, 9, 24, 29, 40, 43, 69, 83, 86, 90, 132, 137, 147, 158, 159, 176, 177, 178, 181 Sleep log, 42, 43, 47, 55, 58, 61, 73, 77, 92, 93 Sleep paralysis, 42, 77, 92, 103, 143, 146, 147 Sleep restriction, 74, 77, 105, 113, 146, 160, 161, 162, 168 Sleep state misperception (SSM), 5, 7, 25, 26, 27, 28, 40, 41, 71, 81, 89, 90, 91, 92, 95, 158, 159, 160, 173 Sleep terrors, 128, 180 Sleep-onset association disorder, 54, 61, 84, 103 Sleep–wake center, 58, 59, 61, 62, 82, 84 Slow-wave sleep, 26, 31, 137, 173 Smith-Magenis syndrome, 61 Stage 1 sleep, 69, 90 Stage 2 sleep, 83, 90 Stage 3 sleep, 26, 90, 181 Stage 4 sleep, 26, 90, 178, 181 Stimulant, 43, 57, 72, 73, 85, 95, 100, 128, 138, 143 Stimulus control therapy, 74, 105, 160, 162, 165, 168, 182 Stroke, 54, 120 Substance abuse, 5, 8, 15, 73, 137, 139, 180 Suprachiasmatic nucleus, 100 T Temazepam, 74, 77, 112, 176, 179 Theophylline, 43, 72, 112 Thyroid, 85, 109, 115, 119 Tiagabine, 121 Time in bed (TIB), 25, 26, 27, 32, 77, 161 Tolerance, 74, 85, 174, 178, 180, 181, 182, 183 Total sleep time (TST), 4, 8, 9, 26, 27, 31, 32, 33, 74, 90, 158, 159, 160, 161, 162, 168 Toxin-induced sleep disorder, 72, 103
- Page 1 and 2:
Clinical Handbook of Insomnia Edite
- Page 3 and 4:
C URRENT CLINICAL NEUROLOGY Daniel
- Page 5 and 6:
© 2004 Humana Press Inc. 999 River
- Page 8:
Series Editor’s Introduction The
- Page 11 and 12:
x Foreword nervous system hypersomn
- Page 14 and 15:
Contents Series Editor’s Introduc
- Page 16:
Contributors HRAYR P. ATTARIAN, MD
- Page 19 and 20:
2 Attarian et al.
- Page 21 and 22:
4 Attarian et al. until the 1970s t
- Page 23 and 24:
6 Attarian et al. Table 2 Diagnosti
- Page 25 and 26:
8 Attarian et al. Duration of Illne
- Page 27 and 28:
10 Attarian et al. REFERENCES 1. Ma
- Page 29 and 30:
12 Attarian Another study in Austri
- Page 31 and 32:
14 Attarian even less well studied.
- Page 33 and 34:
16 Attarian communities. A structur
- Page 35 and 36:
18 Attarian 5. Sutton, D. A., Moldo
- Page 37 and 38:
20 Attarian 53. Kageyama, T., Kabut
- Page 39 and 40:
22 Attarian
- Page 41 and 42:
24 Bonnet and Arand Table 1 Reporte
- Page 43 and 44:
26 Bonnet and Arand On the day spen
- Page 45 and 46:
28 Bonnet and Arand SUMMARY These m
- Page 47 and 48:
30 Bonnet and Arand chronic caffein
- Page 49 and 50:
32 Bonnet and Arand response that a
- Page 51 and 52:
34 Bonnet and Arand The Development
- Page 53 and 54:
36 Bonnet and Arand ACKNOWLEDGMENT
- Page 55 and 56:
38 Bonnet and Arand 45. Bonnet, M.
- Page 57 and 58:
40 Attarian Table 1 Types of Insomn
- Page 59 and 60:
42 Attarian 15 to 40 seconds. PLMs
- Page 61 and 62:
44 Fig. 1. Example of a 1-week slee
- Page 63 and 64:
46 Fig. 3. One-week printout of an
- Page 65 and 66:
48 Attarian Fig. 4. Algorithm. (Use
- Page 67 and 68:
50 Attarian 27. Polo-Kantola, P., E
- Page 69 and 70:
52 Garcia
- Page 71 and 72:
54 Garcia association is known as s
- Page 73 and 74:
56 Fig. 1. A sleep log used in chil
- Page 75 and 76:
58 Garcia the reality that the tend
- Page 77 and 78:
60 Fig. 2. Actigraph recording in a
- Page 79 and 80:
62 Garcia neurodevelopmental disabi
- Page 81 and 82:
64 Garcia 35. Czeisler, C., kronaue
- Page 83 and 84:
66 Garcia
- Page 85 and 86:
68 Attarian showed similar degrees
- Page 87 and 88:
70 Attarian agitation and hence the
- Page 89 and 90:
72 Attarian Affective disorder is s
- Page 91 and 92:
74 Attarian and Drug Administration
- Page 93 and 94:
76 Fig. 2. Sleep log after treatmen
- Page 95 and 96:
78 Attarian 18. Bonnet, M. H. and A
- Page 97 and 98:
80 Attarian 65. Perlis, M., Aloia,
- Page 99 and 100:
82 Attarian was confirmed by resear
- Page 101 and 102:
84 Attarian times worrying about th
- Page 103 and 104:
86 Attarian insomnia or for other s
- Page 105 and 106:
88 Attarian
- Page 107 and 108:
90 Duntley tion systems found that
- Page 109 and 110:
92 Duntley Case 1 A 36-year-old fem
- Page 111 and 112:
94 Fig. 2. The objective amount of
- Page 113 and 114:
96 Duntley PROGNOSIS AND COMPLICATI
- Page 115 and 116:
98 Duntley
- Page 117 and 118:
100 Attarian EPIDEMIOLOGY There are
- Page 119 and 120:
102 Attarian CLINICAL MANIFESTATION
- Page 121 and 122:
104 Attarian DIAGNOSTIC WORKUP The
- Page 123 and 124:
106 Attarian 13. Hauri, P. J. (1998
- Page 125 and 126:
108 Plotkin
- Page 127 and 128:
110 Plotkin quality of sleep. Ultim
- Page 129 and 130:
112 Plotkin of the therapeutic effi
- Page 131 and 132:
114 Plotkin months or years. The ef
- Page 133 and 134:
116 Plotkin associated somatic disc
- Page 135 and 136:
118 Plotkin Table 1 Causes of Secon
- Page 137 and 138:
120 Plotkin Table 1 (continued) Lew
- Page 139 and 140:
122 Plotkin REFERENCES 1. Foley, D.
- Page 141 and 142:
124 Plotkin 48. Marchetti, F., Rome
- Page 143 and 144:
126 Plotkin
- Page 145 and 146:
128 Karaz Table 1 DSM-IV Diagnoses
- Page 147 and 148:
130 Karaz poor. Focusing only on th
- Page 149 and 150:
132 Karaz He felt hopeless that his
- Page 151 and 152:
134 Karaz Table 4 Diagnostic Criter
- Page 153 and 154:
136 Karaz complained of feeling anx
- Page 155 and 156: 138 Karaz other physicians avoided
- Page 157 and 158: 140 Karaz 17. Attarian, H. P. (2000
- Page 159 and 160: 142 Duntley disorders has been conf
- Page 161 and 162: 144 Duntley itance. A recent study
- Page 163 and 164: 146 Duntley The patient’s primary
- Page 165 and 166: 148 Duntley return to sleep. He tos
- Page 167 and 168: 150 Duntley Treatment of RLS should
- Page 169 and 170: 152 Duntley 34. Cartwright, R. (197
- Page 171 and 172: 154 Perlis et al.
- Page 173 and 174: 156 Perlis et al. Fig. 1. A schemat
- Page 175 and 176: 158 Perlis et al. ditioned arousal
- Page 177 and 178: 160 Perlis et al. subjected to empi
- Page 179 and 180: 162 Perlis et al. effect), (3) may
- Page 181 and 182: 164 Perlis et al. Cognitive Therapy
- Page 183 and 184: 166 Perlis et al. Table 2 Cognitive
- Page 185 and 186: 168 Perlis et al. Perhaps more impo
- Page 187 and 188: 170 Perlis et al. 28. Carskadon, M.
- Page 189 and 190: 172 Perlis et al.
- Page 191 and 192: 174 Attarian Secondary Insomnias Re
- Page 193 and 194: 176 Attarian 50 years of age who sl
- Page 195 and 196: 178 Attarian Antidepressants Becaus
- Page 197 and 198: 180 Attarian The use of benzodiazep
- Page 199 and 200: 182 Attarian to placebo. Zaleplon a
- Page 201 and 202: 184 Attarian 3. Wyatt, R. J., Engel
- Page 203 and 204: 186 Attarian residual sedation foll
- Page 205: 188 Index Clonidine, 183 CNS arousa
- Page 209: Current Clinical Neurology CLINICAL